Precision Cancer Therapies, Immunologic Approaches for the Treatment of Lymphoid Malignancies

Provides a definitive, state-of-the-art review of relevant tumor biology and its importance in the broader context of cancer biology

Over the past two decades, a better understanding of the biology of lymphoid malignancies has led to the development of many classes of new, highly active drugs that present opportunities to impact the clinical outcome of many patients.

Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies, focuses on agents that mediate cell killing in lymphoma through a variety of immunologic mechanisms. This authoritative reference covers targeting of cell surface receptors, antibody-drug conjugates (ADC), targeting immune checkpoint, targeting macrophages, EBV-directed immunotherapies, tumor-associated antigens (TAA), and chimeric antigen receptor T-cells (CAR-T).

In-depth chapters on specific therapeutics or therapeutic classes include a basic explanation of the underlying pathway and target, the pharmacology of the drug/class, relevant preclinical and clinical data, and discussion of clinical management and potential predictive biomarkers of response. Information on monotherapy and combination therapy, summary tables of trials, discussion of toxicity and efficacy, and boxed sections highlighting major points are integrated throughout the text.

Authored and edited by the foremost authorities in the field, Precision Cancer Therapies, Volume Two: Immunologic Approaches for the Treatment of Lymphoid Malignancies is an indispensable resource for medical, scientific, and allied medical professionals.

The Precision Cancer Therapies series helps professionals understand and translate fundamental basic science into information that can be directly applied to patients to advance care. Each volume of the series integrates the relevant biological concepts and principles necessary for translating this science to practitioners.